Magrolimab, a monoclonal antibody targeting CD47, an interesting signaling pathway which is interpreted as “Don’t eat me” by tumor-infiltrating macrophages, has showed potential activity for effectively treating TP53-mutated AML. This evidence concerns the gene TP53 and neoplasm.